Paper32150618
In Vitro Antiviral Activity and Projection of Optimized Dosing Design of Hydroxychloroquine for the Treatment of Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2).
Yao X and 14 others. Clin Infect Dis, 2020. Cited by 1,665 papers, by iCite.
Cite this record
ConductScience Library. In Vitro Antiviral Activity and Projection of Optimized Dosing Design of Hydroxychloroquine for the Treatment of Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2). Papers, record 32150618. Release papers-2026-11-12-0.1.0, 12 Nov 2026. https://conductscience.org/library/papers/32150618
- Disease
- COVID-19540 drugs
- Sources
- 11 sources
- Release
- papers-2026-11-12-0.1.0
Paper
PubMed's record of the paper, with iCite's citation figures. No abstract is shown.
- Title
- In Vitro Antiviral Activity and Projection of Optimized Dosing Design of Hydroxychloroquine for the Treatment of Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2).
- PubMed
Connected records2
Records in the library's other databases whose lists name this one, each read from that database's own release: up to 20 of each kind, the most connected first.
Topics16
NLM's MeSH indexing of the paper, its major topics first.
| MeSH term | Major |
|---|---|
| Antiviral Agents | Major topic |
| Betacoronavirus | Major topic |
| Coronavirus Infections | Major topic |
| Hydroxychloroquine | Major topic |
| Pneumonia, Viral | Major topic |
| Severe Acute Respiratory Syndrome | Major topic |
| Animals | |
| COVID-19 | |
| Cell Line | |
| Chlorocebus aethiops | |
| Chloroquine | |
| Lung | |
| Pandemics | |
| SARS-CoV-2 | |
| Vero Cells | |
| COVID-19 Drug Treatment |
Source PubMed
Trials17
The trials whose ClinicalTrials.gov record lists the paper, and the trial numbers the paper's PubMed record names.
| Trial | Title | The trial lists it as | Named in the paper's record | Source |
|---|---|---|---|---|
| NCT04334967 | Hydroxychloroquine in Patients With Newly Diagnosed COVID-19 Compared to Standard of Care | Background | ClinicalTrials.gov | |
| NCT04339816 | Azithromycin Added to Hydrochloroquine in Patients Admitted to Intensive Care With COVID-19: Randomised Controlled Trial | Background | ClinicalTrials.gov | |
| NCT04340349 | Low-dose Hydroxychloroquine and Bromhexine: a Novel Regimen for COVID-19 Prophylaxis in Healthcare Professionals | Results | ClinicalTrials.gov | |
| NCT04341441 | Will Hydroxychloroquine Impede or Prevent COVID-19 | Background | ClinicalTrials.gov | |
| NCT04345289 | Efficacy and Safety of Novel Treatment Options for Adults With COVID-19 Pneumonia | Background | ClinicalTrials.gov | |
| NCT04353271 | Trial of Hydroxychloroquine In Covid-19 Kinetics | Background | ClinicalTrials.gov | |
| NCT04354441 | Effect of Hydroxychloroquine in COVID-19 Positive Pregnant Women | Background | ClinicalTrials.gov | |
| NCT04359095 | Effectiveness and Safety of Medical Treatment for SARS-CoV-2 (COVID-19) in Colombia | Results | ClinicalTrials.gov | |
| NCT04361318 | Hydroxychloroquine and Nitazoxanide Combination Therapy for COVID-19 | Background | ClinicalTrials.gov | |
| NCT04369989 | Observational Study of COVID-19 Treatment Efficacy | Background | ClinicalTrials.gov | |
| NCT04370782 | Hydroxychloroquine and Zinc With Either Azithromycin or Doxycycline for Treatment of COVID-19 in Outpatient Setting | Background | ClinicalTrials.gov | |
| NCT04380870 | Describing Chinese Herbal Medicine Telehealth Care for Symptoms Related to Infectious Diseases Such as COVID-19 | Background | ClinicalTrials.gov | |
| NCT04394416 | Trial of Imatinib for Hospitalized Adults With COVID-19 | Background | ClinicalTrials.gov | |
| NCT04434144 | A Comparative Study on Ivermectin and Hydroxychloroquine on the COVID19 Patients in Bangladesh | Background | ClinicalTrials.gov | |
| NCT04491994 | Clearing the Fog: Is Hydroxychloroquine Effective in Reducing COVID-19 Progression | Background | ClinicalTrials.gov | |
| NCT04627467 | Prevention With Chloroquine in Health Personnel Exposed to Infection With Coronavirus Disease 2019 (COVID-19) (TS-COVID) | Results | ClinicalTrials.gov | |
| NCT04654416 | Clinical Outcome of Patients With COVID-19 Pneumonia Treated With Corticosteroids and Colchicine | Background | ClinicalTrials.gov |
Comments and corrections9
PubMed's comments and corrections, NLM's own indexing: retractions first, then expressions of concern, errata and updates, and comments last.
| Kind | PMID | Title | In Papers | Source |
|---|---|---|---|---|
| Comment in | 32211764 | Is Hydroxychloroquine a Possible Postexposure Prophylaxis Drug to Limit the Transmission to Healthcare Workers Exposed to Coronavirus Disease 2019? | https://conductscience.org/library/papers/32211764 | PubMed |
| Comment in | 32211771 | Could Chloroquine /Hydroxychloroquine Be Harmful in Coronavirus Disease 2019 (COVID-19) Treatment? | https://conductscience.org/library/papers/32211771 | PubMed |
| Comment in | 32215614 | Hydroxychloroquine and Chloroquine. | https://conductscience.org/library/papers/32215614 | PubMed |
| Comment in | 32241791 | To consider or not antimalarials as a prophylactic intervention in the SARS-CoV-2 (Covid-19) pandemic. | https://conductscience.org/library/papers/32241791 | PubMed |
| Comment in | 32268005 | Hydroxychloroquine for Treatment of SARS-CoV-2 Infection? Improving Our Confidence in a Model-Based Approach to Dose Selection. | https://conductscience.org/library/papers/32268005 | PubMed |
| Comment in | 32607540 | Simulation of Drug in the Lung Can Be Misleading. | https://conductscience.org/library/papers/32607540 | PubMed |
| Comment in | 32613227 | Reply to Wolowich and Kwon. | https://conductscience.org/library/papers/32613227 | PubMed |
| Comment in | 33170206 | Response to Jia and Wang. | https://conductscience.org/library/papers/33170206 | PubMed |
| Comment in | 33258095 | Coronavirus Disease 2019 (COVID-19) Spread and Pharmacovigilance Implications: Expert Opinion. | https://conductscience.org/library/papers/33258095 | PubMed |
Cited by1,394
The papers in our copy of PubMed whose reference list names this one, newest first. iCite, which reads more sources, counts 1,665 citations.
| PMID | Title | Journal | Year | In Papers | Source |
|---|---|---|---|---|---|
| 42634088 | Pediatric Use of Off-Label Medicines and Nonevidence-Based Supplements for COVID-19: Findings From the 2015 Pelotas Birth Cohort Study (Brazil). | Pharmacoepidemiol Drug Saf | 2026 | https://conductscience.org/library/papers/42634088 | PubMed |
| 42515655 | Drug Repurposing as a Broad-Spectrum Strategy Against Coronaviruses: Frontiers in Mechanisms and Clinical Translation. | Viruses | 2026 | https://conductscience.org/library/papers/42515655 | PubMed |
| 42400597 | Best Practices in Physiologically Based Pharmacokinetic (PBPK) Modeling. | CPT Pharmacometrics Syst Pharmacol | 2026 | https://conductscience.org/library/papers/42400597 | PubMed |
| 41708603 | cGAS-IFN-I responses by extracting nuclear DNA from dying cells via nucleocytosis. | Nat Commun | 2026 | https://conductscience.org/library/papers/41708603 | PubMed |
| 41551435 | Magic bullets, magic shields, and antimicrobials in between. | Pharm Sci Adv | 2023 | https://conductscience.org/library/papers/41551435 | PubMed |
| 41550857 | Strategic Preparedness of Broad-Spectrum Antivirals for Rapid Response Towards Next Pandemics. | Small Sci | 2026 | https://conductscience.org/library/papers/41550857 | PubMed |
| 41535311 | Evaluation of the cardiopulmonary effects of repurposed COVID-19 therapeutics in healthy rats. | Sci Rep | 2026 | https://conductscience.org/library/papers/41535311 | PubMed |
| 40771916 | Degradation of IRAK4 for the treatment of lipopolysaccharide-induced acute lung injury in mice. | Front Pharmacol | 2025 | https://conductscience.org/library/papers/40771916 | PubMed |
| 40665189 | Nasal inhalation of antiviral microparticulate powders to target early infection of upper airways. | Drug Deliv Transl Res | 2026 | https://conductscience.org/library/papers/40665189 | PubMed |
| 40615618 | The PRINCIPLE randomised controlled open label platform trial of hydroxychloroquine for treating COVID19 in community based patients at high risk. | Sci Rep | 2025 | https://conductscience.org/library/papers/40615618 | PubMed |
| 40535766 | Antimalarial compounds exhibit variant- and cell-type-specific activity against SARS-CoV-2 isolated in Panama. | Front Pharmacol | 2025 | https://conductscience.org/library/papers/40535766 | PubMed |
| 40476966 | [Recommendations for rheumatologists on pharmacological management during the COVID-19 health emergency: Expert group opinion]. | Rev Colomb Reumatol | 2021 | https://conductscience.org/library/papers/40476966 | PubMed |
| 40476913 | A review on the immunomodulatory properties of functional nutraceuticals as dietary interventions for children to combat COVID-19 related infections. | Food Prod Process Nutr | 2023 | https://conductscience.org/library/papers/40476913 | PubMed |
| 40289186 | Hydroxychloroquine use during the first COVID-19 wave: a case study highlighting the urgent need to enhance research practices within the publication ecosystem. | Arch Public Health | 2025 | https://conductscience.org/library/papers/40289186 | PubMed |
| 40161134 | Safety of Hydroxychloroquine for COVID-19 Prophylaxis in Healthcare Workers: A Cross-Sectional Study. | Cureus | 2025 | https://conductscience.org/library/papers/40161134 | PubMed |
| 40122800 | A new paradigm for drug discovery in the treatment of complex diseases: drug discovery and optimization. | Chin Med | 2025 | https://conductscience.org/library/papers/40122800 | PubMed |
| 40074774 | Malabaricone C isolated from edible plants as a potential inhibitor of SARS-CoV-2 infection. | Sci Rep | 2025 | https://conductscience.org/library/papers/40074774 | PubMed |
| 40035964 | Low dose of hydroxychloroquine is associated with reduced COVID-19 mortality: a multicenter study in China. | Front Med | 2025 | https://conductscience.org/library/papers/40035964 | PubMed |
| 40007183 | Exploring Quinoline Derivatives: Their Antimalarial Efficacy and Structural Features. | Med Chem | 2025 | https://conductscience.org/library/papers/40007183 | PubMed |
| 39896318 | Exploration of innovative drug repurposing strategies for combating human protozoan diseases: Advances, challenges, and opportunities. | J Pharm Anal | 2025 | https://conductscience.org/library/papers/39896318 | PubMed |
Genes7
The genes the Gene search release ties to the paper: Swiss-Prot's references first, then PubTator's text mining.
| Gene | NCBI Gene ID | Linked by | In Genes | Source |
|---|---|---|---|---|
| ALB | 213 | PubTator's text mining | https://conductscience.org/library/genes/213 | NCBI Gene |
| C1QA | 712 | PubTator's text mining | https://conductscience.org/library/genes/712 | NCBI Gene |
| C3 | 718 | PubTator's text mining | https://conductscience.org/library/genes/718 | NCBI Gene |
| CD79A | 973 | PubTator's text mining | https://conductscience.org/library/genes/973 | NCBI Gene |
| MPO | 4353 | PubTator's text mining | https://conductscience.org/library/genes/4353 | NCBI Gene |
| PLA2R1 | 22925 | PubTator's text mining | https://conductscience.org/library/genes/22925 | NCBI Gene |
| PRTN3 | 5657 | PubTator's text mining | https://conductscience.org/library/genes/5657 | NCBI Gene |
Drugs8
The drugs whose trials, in the Pipelines release, list the paper.
| Drug | ChEMBL ID | The trials list it as | Trials | In Drugs and targets | Source |
|---|---|---|---|---|---|
| COLCHICINE | CHEMBL107 | Results | 1 | https://conductscience.org/library/drugs/CHEMBL107 | ChEMBL |
| ROSUVASTATIN | CHEMBL1496 | Results | 1 | https://conductscience.org/library/drugs/CHEMBL1496 | ChEMBL |
| HYDROXYCHLOROQUINE | CHEMBL1535 | Results | 1 | https://conductscience.org/library/drugs/CHEMBL1535 | ChEMBL |
| EMTRICITABINE, (+/-)- | CHEMBL161381 | Results | 1 | https://conductscience.org/library/drugs/CHEMBL161381 | ChEMBL |
| BROMHEXINE | CHEMBL253376 | Results | 1 | https://conductscience.org/library/drugs/CHEMBL253376 | ChEMBL |
| TENOFOVIR | CHEMBL3989702 | Results | 1 | https://conductscience.org/library/drugs/CHEMBL3989702 | ChEMBL |
| CHLOROQUINE | CHEMBL76 | Results | 1 | https://conductscience.org/library/drugs/CHEMBL76 | ChEMBL |
| EMTRICITABINE | CHEMBL885 | Results | 1 | https://conductscience.org/library/drugs/CHEMBL885 | ChEMBL |
Data dates
The date of each source this release read.
- Trials
- 2026-11-12
- Gene search
- 2026-11-11
- Pipelines
- 2026-09-18
None in this release
- Grants
- References
- Data
Sources 11
- ChEMBL, through Open TargetsCC BY-SA 3.0
- ClinicalTrials.govNo license stated
- HGNCCC0
- iCiteCC BY 4.0
- NCBI GenePublic domain (US government)
- NIH RePORTER's grant and paper linksPublic domain
- Open TargetsCC0 1.0
- PMC's ID filePublic domain (US government)
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0
Each source's terms
- ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- ClinicalTrials.govnone stated
- HGNCCC0: https://www.genenames.org/about/license/
- iCiteCC BY 4.0
- NCBI GeneNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
- NIH RePORTER's grant and paper linksPublic domain (NIH RePORTER)
- Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- PMC's ID fileNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0. UniProt's licence file: "All databases and documents in the UniProt FTP directory may be copied and redistributed freely, without advance permission, provided that this copyright statement is reproduced with each copy." UniProt asks that users cite its latest paper: The UniProt Consortium, UniProt: the Universal Protein Knowledgebase in 2025, Nucleic Acids Research 53:D609-D617, https://doi.org/10.1093/nar/gkae1010. Read on 9 Nov 2026 at https://www.uniprot.org/help/license
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this paper from software.
The record and each of its lists are JSON, twenty rows a page. No key.
GET https://conductscience.org/api/papers/v1/32150618
GET https://conductscience.org/api/papers/v1/32150618/cited_by?page=2